Nitric oxide-induced resistance or sensitization to death in tumor cells

Nitric Oxide - Biology and Chemistry

Volumn 19, Issue 2, 2008, Pages 158-163

  Jeannin, Jean François ^a,b,c   Leon, Lissbeth ^a,b,c   Cortier, Marion ^a,b,c   Sassi, Néjia ^a,b,c   Paul, Catherine ^a,b,c   Bettaieb, Ali ^a,b,c  

^a PSL RESEARCH UNIVERSITY   (France)

^b Institut Médical de Génétique et d Immunologie   (France)

^c UNIVERSITÉ DE BOURGOGNE   (France)

Author keywords

Apoptosis; Cytokine; Cytotoxic drug; Ionizing radiation; Microenvironment

Indexed keywords

CYTOTOXIC AGENT; NITRIC OXIDE; TUMOR NECROSIS FACTOR;

APOPTOSIS; CANCER INHIBITION; CYTOTOXICITY; HUMAN; IONIZING RADIATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS; APOPTOSIS; HUMANS; NEOPLASMS; NITRIC OXIDE; RADIOTHERAPY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 47049129854     PISSN: 10898603     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.niox.2008.04.024     Document Type: Review

References (57)

1. Gauthier N., Lohm S., Touzery C., Chantome A., Perette B., Reveneau S., Brunotte F., Juillerat-Jeanneret L., and Jeannin J.F. Tumour-derived and host-derived nitric oxide differentially regulate breast carcinoma metastasis to the lungs. Carcinogenesis 25 (2004) 1559-1565
2. Lejeune P., Lagadec P., Onier N., Pinard D., Ohshima H., and Jeannin J.F. Nitric oxide involvement in tumor-induced immunosuppression. J. Immunol. 152 (1994) 5077-5083
3. Jadeski L.C., Chakraborty C., and Lala P.K. Nitric oxide-mediated promotion of mammary tumour cell migration requires sequential activation of nitric oxide synthase, guanylate cyclase and mitogen-activated protein kinase. Int. J. Cancer 106 (2003) 496-504
4. Thomsen L.L., Scott J.M., Topley P., Knowles R.G., Keerie A.J., and Frend A.J. Selective inhibition of inducible nitric oxide synthase inhibits tumor growth in vivo: studies with 1400W, a novel inhibitor. Cancer Res. 57 (1997) 3300-3304
5. Jadeski L.C., and Lala P.K. Nitric oxide synthase inhibition by N(G)-nitro-l-arginine methyl ester inhibits tumor-induced angiogenesis in mammary tumors. Am. J. Pathol. 155 (1999) 1381-1390
6. Lagadec P., Raynal S., Lieubeau B., Onier N., Arnould L., Saint-Giorgio V., Lawrence D.A., and Jeannin J.F. Evidence for control of nitric oxide synthesis by intracellular transforming growth factor-beta1 in tumor cells. Implications for tumor development. Am. J. Pathol. 154 (1999) 1867-1876
7. Zhao H., Dugas N., Mathiot C., Delmer A., Dugas B., Sigaux F., and Kolb J.P. B-cell chronic lymphocytic leukemia cells express a functional inducible nitric oxide synthase displaying anti-apoptotic activity. Blood 92 (1998) 1031-1043
8. Tang C.H., and Grimm E.A. Depletion of endogenous nitric oxide enhances cisplatin-induced apoptosis in a p53-dependent manner in melanoma cell lines. J. Biol. Chem. 279 (2004) 288-298
9. Chanvorachote P., Nimmannit U., Stehlik C., Wang L., Jiang B.H., Ongpipatanakul B., and Rojanasakul Y. Nitric oxide regulates cell sensitivity to cisplatin-induced apoptosis through S-nitrosylation and inhibition of Bcl-2 ubiquitination. Cancer Res. 66 (2006) 6353-6360
10. Kim Y.M., Kim T.H., Seol D.W., Talanian R.V., and Billiar T.R. Nitric oxide suppression of apoptosis occurs in association with an inhibition of Bcl-2 cleavage and cytochrome c release. J. Biol. Chem. 273 (1998) 31437-31441
11. Aguilar-Santelises M., Mozart M., Scuderi R., and Celsing F. Altered expression of key cellular gene products accompanies development of resistance to nitric oxide. Nitric Oxide 15 (2006) 328-336
12. Liu L., and Stamler J.S. NO: an inhibitor of cell death. Cell Death Differ. 6 (1999) 937-942
13. Garban H.J., and Bonavida B. Nitric oxide sensitizes ovarian tumor cells to Fas-induced apoptosis. Gynecol. Oncol. 73 (1999) 257-264
14. Millet A., Bettaieb A., Renaud F., Prevotat L., Hammann A., Solary E., Mignotte B., and Jeannin J.F. Influence of the nitric oxide donor glyceryl trinitrate on apoptotic pathways in human colon cancer cells. Gastroenterology 123 (2002) 235-246
15. Lee Y.J., Lee K.H., Kim H.R., Jessup J.M., Seol D.W., Kim T.H., Billiar T.R., and Song Y.K. Sodium nitroprusside enhances TRAIL-induced apoptosis via a mitochondria-dependent pathway in human colorectal carcinoma CX-1 cells. Oncogene 20 (2001) 1476-1485
16. Bauer J.A., Morrison B.H., Grane R.W., Jacobs B.S., Dabney S., Gamero A.M., Carnevale K.A., Smith D.J., Drazba J., Seetharam B., and Lindner D.J. Effects of interferon beta on transcobalamin II-receptor expression and antitumor activity of nitrosylcobalamin. J. Natl. Cancer. Inst. 94 (2002) 1010-1019
17. Chawla-Sarkar M., Bauer J.A., Lupica J.A., Morrison B.H., Tang Z., Oates R.K., Almasan A., DiDonato J.A., Borden E.C., and Lindner D.J. Suppression of NF-kappa B survival signaling by nitrosylcobalamin sensitizes neoplasms to the anti-tumor effects of Apo2L/TRAIL. J. Biol. Chem. 278 (2003) 39461-39469
18. Huerta-Yepez S., Vega M., Jazirehi A., Garban H., Hongo F., Cheng G., and Bonavida B. Nitric oxide sensitizes prostate carcinoma cell lines to TRAIL-mediated apoptosis via inactivation of NF-kappa B and inhibition of Bcl-xl expression. Oncogene 23 (2004) 4993-5003
19. Secchiero P., Gonelli A., Celeghini C., Mirandola P., Guidotti L., Visani G., Capitani S., and Zauli G. Activation of the nitric oxide synthase pathway represents a key component of tumor necrosis factor-related apoptosis-inducing ligand-mediated cytotoxicity on hematologic malignancies. Blood 98 (2001) 2220-2228
20. Garban H.J., and Bonavida B. Nitric oxide disrupts H2O2-dependent activation of nuclear factor kappa B. Role in sensitization of human tumor cells to tumor necrosis factor-alpha-induced cytotoxicity. J. Biol. Chem. 276 (2001) 8918-8923
21. Huang J., Tatsumi T., Pizzoferrato E., Vujanovic N., and Storkus W.J. Nitric oxide sensitizes tumor cells to dendritic cell-mediated apoptosis, uptake, and cross-presentation. Cancer Res. 65 (2005) 8461-8470
22. Evig C.B., Kelley E.E., Weydert C.J., Chu Y., Buettner G.R., and Burns C.P. Endogenous production and exogenous exposure to nitric oxide augment doxorubicin cytotoxicity for breast cancer cells but not cardiac myoblasts. Nitric Oxide 10 (2004) 119-129
23. Muir C.P., Adams M.A., and Graham C.H. Nitric oxide attenuates resistance to doxorubicin in three-dimensional aggregates of human breast carcinoma cells. Breast Cancer Res. Treat. 96 (2006) 169-176
24. Wink D.A., Cook J.A., Christodoulou D., Krishna M.C., Pacelli R., Kim S., DeGraff W., Gamson J., Vodovotz Y., Russo A., and Mitchell J.B. Nitric oxide and some nitric oxide donor compounds enhance the cytotoxicity of cisplatin. Nitric Oxide 1 (1997) 88-94
25. Azizzadeh B., Yip H.T., Blackwell K.E., Horvath S., Calcaterra T.C., Buga G.M., Ignarro L.J., and Wang M.B. Nitric oxide improves cisplatin cytotoxicity in head and neck squamous cell carcinoma. Laryngoscope 111 (2001) 1896-1900
26. Liu J., Li C., Qu W., Leslie E., Bonifant C.L., Buzard G.S., Saavedra J.E., Keefer L.K., and Waalkes M.P. Nitric oxide prodrugs and metallochemotherapeutics: JS-K and CB-3-100 enhance arsenic and cisplatin cytolethality by increasing cellular accumulation. Mol. Cancer Ther. 3 (2004) 709-714
27. Son K.K., and Hall K.J. Nitric oxide-mediated tumor cell killing of cisplatin-based interferon-gamma gene therapy in murine ovarian carcinoma. Cancer Gene Ther. 7 (2000) 1324-1328
28. Cook J.A., Krishna M.C., Pacelli R., DeGraff W., Liebmann J., Mitchell J.B., Russo A., and Wink D.A. Nitric oxide enhancement of melphalan-induced cytotoxicity. Br. J. Cancer 76 (1997) 325-334
29. Adams D.J., Levesque M.C., Weinberg J.B., Smith K.L., Flowers J.L., Moore J., Colvin O.M., and Silber R. Nitric oxide enhancement of fludarabine cytotoxicity for B-CLL lymphocytes. Leukemia 15 (2001) 1852-1859
30. Yasuda H., Yamaya M., Nakayama K., Sasaki T., Ebihara S., Kanda A., Asada M., Inoue D., Suzuki T., Okazaki T., Takahashi H., Yoshida M., Kaneta T., Ishizawa K., Yamanda S., Tomita N., Yamasaki M., Kikuchi A., Kubo H., and Sasaki H. Randomized phase II trial comparing nitroglycerin plus vinorelbine and cisplatin with vinorelbine and cisplatin alone in previously untreated stage IIIB/IV non-small-cell lung cancer. J. Clin. Oncol. 24 (2006) 688-694
31. Verovski V.N., Van den Berge D.L., Soete G.A., Bols B.L., and Storme G.A. Intrinsic radiosensitivity of human pancreatic tumour cells and the radiosensitising potency of the nitric oxide donor sodium nitroprusside. Br. J. Cancer 74 (1996) 1734-1742
32. Griffin R.J., Makepeace C.M., Hur W.J., and Song C.W. Radiosensitization of hypoxic tumor cells in vitro by nitric oxide. Int. J. Radiat. Oncol. Biol. Phys. 36 (1996) 377-383
33. Janssens M.Y., Verovski V.N., Van den Berge D.L., Monsaert C., and Storme G.A. Radiosensitization of hypoxic tumour cells by S-nitroso-N-acetylpenicillamine implicates a bioreductive mechanism of nitric oxide generation. Br. J. Cancer 79 (1999) 1085-1089
34. Worthington J., Robson T., O'Keeffe M., and Hirst D.G. Tumour cell radiosensitization using constitutive (CMV) and radiation inducible (WAF1) promoters to drive the iNOS gene: a novel suicide gene therapy. Gene Ther. 9 (2002) 263-269
35. Kurimoto M., Endo S., Hirashima Y., Hamada H., Ogiichi T., and Takaku A. Growth inhibition and radiosensitization of cultured glioma cells by nitric oxide generating agents. J. Neurooncol. 42 (1999) 35-44
36. Wang Z., Cook T., Alber S., Liu K., Kovesdi I., Watkins S.K., Vodovotz Y., Billiar T.R., and Blumberg D. Adenoviral gene transfer of the human inducible nitric oxide synthase gene enhances the radiation response of human colorectal cancer associated with alterations in tumor vascularity. Cancer Res. 64 (2004) 1386-1395
37. Wood P.J., Sansom J.M., Stratford I.J., Adams G.E., Szabo C., Thiemermann C., and Vane J.R. Changes in energy metabolism and X-ray sensitivity in murine tumours by the nitric oxide donor SIN-1. Br. J. Cancer Suppl. 27 (1996) S177-S180
38. Jordan B.F., Beghein N., Aubry M., Gregoire V., and Gallez B. Potentiation of radiation-induced regrowth delay by isosorbide dinitrate in FSaII murine tumors. Int. J. Cancer 103 (2003) 138-141
39. Green D.R. Overview: apoptotic signaling pathways in the immune system. Immunol. Rev. 193 (2003) 5-9
40. Li P., Nijhawan D., Budihardjo I., Srinivasula S.M., Ahmad M., Alnemri E.S., and Wang X. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 91 (1997) 479-489
41. Thornberry N.A., and Lazebnik Y. Caspases: enemies within. Science 281 (1998) 1312-1316
42. Marsden V.S., and Strasser A. Control of apoptosis in the immune system: Bcl-2, BH3-only proteins and more. Annu. Rev. Immunol. 21 (2003) 71-105
43. Hongo F., Garban H., Huerta-Yepez S., Vega M., Jazirehi A.R., Mizutani Y., Miki T., and Bonavida B. Inhibition of the transcription factor Yin Yang 1 activity by S-nitrosation. Biochem. Biophys. Res. Commun. 336 (2005) 692-701
44. Gong B., and Almasan A. Apo2 ligand/TNF-related apoptosis-inducing ligand and death receptor 5 mediate the apoptotic signaling induced by ionizing radiation in leukemic cells. Cancer Res. 60 (2000) 5754-5760
45. Tang Z., Bauer J.A., Morrison B., and Lindner D.J. Nitrosylcobalamin promotes cell death via S nitrosylation of Apo2L/TRAIL receptor DR4. Mol. Cell Biol. 26 (2006) 5588-5594
46. Suh J., Payvandi F., Edelstein L.C., Amenta P.S., Zong W.X., Gelinas C., and Rabson A.B. Mechanisms of constitutive NF-kappaB activation in human prostate cancer cells. Prostate 52 (2002) 183-200
47. Lee H.H., Dadgostar H., Cheng Q., Shu J., and Cheng G. NF-kappaB-mediated up-regulation of Bcl-x and Bfl-1/A1 is required for CD40 survival signaling in B lymphocytes. Proc. Natl. Acad. Sci. USA 96 (1999) 9136-9141
48. Oya M., Ohtsubo M., Takayanagi A., Tachibana M., Shimizu N., and Murai M. Constitutive activation of nuclear factor-kappaB prevents TRAIL-induced apoptosis in renal cancer cells. Oncogene 20 (2001) 3888-3896
49. Riganti C., Miraglia E., Viarisio D., Costamagna C., Pescarmona G., Ghigo D., and Bosia A. Nitric oxide reverts the resistance to doxorubicin in human colon cancer cells by inhibiting the drug efflux. Cancer Res. 65 (2005) 516-525
50. Cook T., Wang Z., Alber S., Liu K., Watkins S.C., Vodovotz Y., Billiar T.R., and Blumberg D. Nitric oxide and ionizing radiation synergistically promote apoptosis and growth inhibition of cancer by activating p53. Cancer Res. 64 (2004) 8015-8021
51. Wang X., Zalcenstein A., and Oren M. Nitric oxide promotes p53 nuclear retention and sensitizes neuroblastoma cells to apoptosis by ionizing radiation. Cell Death Differ. 10 (2003) 468-476
52. Park I.C., Woo S.H., Park M.J., Lee H.C., Lee S.J., Hong Y.J., Lee S.H., Hong S.I., and Rhee C.H. Ionizing radiation and nitric oxide donor sensitize Fas-induced apoptosis via up-regulation of Fas in human cervical cancer cells. Oncol. Rep. 10 (2003) 629-633
53. Chung P., Cook T., Liu K., Vodovotz Y., Zamora R., Finkelstein S., Billiar T., and Blumberg D. Overexpression of the human inducible nitric oxide synthase gene enhances radiation-induced apoptosis in colorectal cancer cells via a caspase-dependent mechanism. Nitric Oxide 8 (2003) 119-126
54. Mannick J.B., Schonhoff C., Papeta N., Ghafourifar P., Szibor M., Fang K., and Gaston B. S-Nitrosylation of mitochondrial caspases. J. Cell Biol. 154 (2001) 1111-1116
55. Hogg N. The biochemistry and physiology of S-nitrosothiols. Annu. Rev. Pharmacol. Toxicol. 42 (2002) 585-600
56. Gaston B.M., Carver J., Doctor A., and Palmer L.A. S-nitrosylation signaling in cell biology. Mol. Interv. 3 (2003) 253-263
57. Mannick J.B., and Schonhoff C.M. Nitrosylation: the next phosphorylation?. Arch. Biochem. Biophys. 408 (2002) 1-6